Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using tissue cell culture to make a protein or polypeptide
Reexamination Certificate
2001-04-12
2009-08-25
Ouspenski, Ilia (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using tissue cell culture to make a protein or polypeptide
C435S069600, C435S007100
Reexamination Certificate
active
07579170
ABSTRACT:
The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
REFERENCES:
patent: 5830470 (1998-11-01), Nakamura et al.
patent: 5843708 (1998-12-01), Hardman et al.
patent: 5851524 (1998-12-01), Beliard et al.
patent: 0 249 557 (1987-12-01), None
patent: 0 251 440 (1988-01-01), None
patent: 0 576 093 (2000-03-01), None
patent: 1 176 195 (2002-01-01), None
patent: 1 229 125 (2002-08-01), None
patent: 2 653 561 (1991-04-01), None
patent: 2653561 (1991-04-01), None
patent: 63-50710 (1988-03-01), None
patent: 2 094 462 (1997-10-01), None
patent: WO-89/02442 (1989-03-01), None
patent: WO-89/02600 (1989-03-01), None
patent: WO 00/61739 (2000-10-01), None
patent: WO 01/29246 (2001-04-01), None
patent: WO 02/30954 (2002-04-01), None
patent: WO 02/31140 (2002-04-01), None
patent: WO 03/055993 (2003-07-01), None
patent: WO 03/084569 (2003-10-01), None
patent: WO 03/084570 (2003-10-01), None
patent: WO 03/085102 (2003-10-01), None
patent: WO 03/085107 (2003-10-01), None
patent: WO 03/085118 (2003-10-01), None
patent: WO 03/085119 (2003-10-01), None
Shepard et al. Vox Sang. 1996. 70:157-163.
Siberil et al. Clinical Immunology. 2006. 118:170-179.
Kilmartin et al. The Journal of Cell Biology. 1982. 93:576-582.
Urbaniak et al Vox Sang. 1984. 46:323-329.
Lown et al. Immunohematology 1995. 11:4.
ATCC Product Description of YB2/0 CRL-1662 and Material Transfer Aggreement . 2003. pp. 1-6.
Janeway et al. Immunobiology by Current Biology Ltd. 1990 Chapter 3, pp. 3:1-3:38.
Genes IV. Lewin et al, Oxford University Press, 1990, p. 810.
Klein et al., “Human recombinant anti-Rh(D) monoclonal antibodies: Improvement of biological properties by in vitro class-switch,” Human Antibodies, vol. 8, No. 1, 1997, pp. 17-25, XP001015726, ISSN: 1093-2607.
Hadley, et al., “The functional activity of Fc.gamma.RII and Fc.gamma.RIII on subsets of human lymphocytes,” Immunology, 1992, vol. 76, No. 3, pp. 446-451, XP001015733.
Bredius et al., “Role of neutrophil Fc-gamma-RIIa (CD32) and Fc-gamma-RIIIb (CD16 polymorphic forms in phagocytosis of human IfG1- and IgG3-opsonized bacteria and erythrocytes,” Immunology, vol. 83, No. 4, 1994, pp. 624-630, XP000971450, ISSN: 0019-2805.
Paterson et al., “Variation in IfF1 heavy chain allotype does not contribute to differences in biological activity of two human anti-Rhesus (D) monoclonal antibodies,” Immunotechnology, Elsevier Science Publishers BV, vol. 4, No. 1, Jun. 1, 1998, pp. 37-47, XP004127385, ISSN: 1380-2933.
Ugen et al., “New recombinant multimer of two fusion proteins, each including part of C4 binding protein; recombinant complement-C4 binding protein and CD4, CD8, CD16, CD35, Rhesus-D, antigen, enzyme or single chain antibody fusion protein multimer for use as a recombinant vaccine or diagnostic,” Vaccine, Butterworth Scientific, Guildford, Great Britain, vol. 15, No. 8, Jun. 1, 1997, p. 935, XP004075692, ISSN: 0264-410X.
Bihoreau et al., “Combination of capillary electrophoresis and matrix-assisted laser description ionization mass spectrometry for glycosylation analysis fo a human monoclonal anti-Rhesus(D) antibody,” Journal of Chromatography B: Biomedical Sciences & Applications, Elsevier Science Publishers, vol. 697, No. 1-2, Sep. 12, 1997, pp. 123-133, XP0004090752, ISSN: 0378-4347.
Hutchins et al., “Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a γ4 variant of Campath-1H,” Proc. Natl. Acad. Sci. USA, Dec. 1995, 92:11980-11984.
Keen, M.J., “The culture of rat myeloma and rat hybridoma cells in a protein-free medium,” Cytotechnology, 1995, 17:193-202.
Lifely et al., “Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions,” Glycobiology, 1995, 5(8):813-822.
Shinkawa et al., “The Absence of Fucose but Not the Presence of Galactose or Bisecting N- Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Crtitical Roel of Enhancing Antibody-dependent Cellular Cytotoxicity,” J. Biol. Chem., Jan. 31, 2003, 278(5):3466-3473.
Shitara et al., “A New vector for the high level expression of chimeric antibodies in myeloma cells,” J. Immun. Methods, 1994, 167:271-278.
Vitetta et al., “Considering Therapeutic Antibodies,” Science, Jul. 21, 2006, 313:308-309.
“WinRho,” (http://www.winrho.com/winrho.html).
Boylston, A. W., et al.; “Production of Human IgM Anti-D in Tissue Culture by EB-Virus-transformed Lymphocytes”; Scand. J. Immunol., 12, 355-358, 1980.
Bron, D. et al.; “Production of human monoclonal IgG antibodies against Rhesus (D) antigen”; Proc. Nat. Acad. Sci., vol. 81, pp. 3214-3217, May 1984.
Chouchane, L., et al.; “Molecular characterization of a human anti-Rh(D) antibody with a DH segment encoded by a germ-line sequence”; Eur. J. Biochem; 207:1115-1121 (1992).
Crawford, D. et al.; “Production of Human Monoclonal Antibody to Rhesus D Antigen”; The Lancet; pp. 386-388; Feb. 19, 1983.
Debré, M.; “Feasibility of administering Tegeline at home Restrospective study of the data concerning efficacy, safety and tolerance”; Pressre Med., 33:682-688 (2004).
Doyle, A. et al.; “In vitro Development of Human Monoclonal Antibody-Secreting Plasmacytomas”; Human Immunology; 13:199-209 (1985).
Edelman, L., et al.; “Obtaining a functional recombinant anti-rhesus (D) antibody using the baculovirus-insect cell expression system”; Immunology 91:13-19 (1997).
Foung, S., et al.; “Human Monoclonal Antibodies to RH0(D)”; Vox Sang; 53:44-47 (1987).
Goossens, D. et al.; “Human monoclonal antibodies against blood group antigens”; Journal of Immunological Methods , 101 (1987) 193-200.
Issitt, P.; “Genetics of the Rh blood group system: some current concepts”; Medical Laboratory Sciences; 45:395-404 (1988).
Jefferis, R. et al.; “A comparative study of the N-linked oligosaccharide structures of human IgC subclass proteins”; Biochem. J. (1990) 268. 529-537.
Jefferis, R. et al.; Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFcyR); Molecular Immunology, vol. 27, No. 12, pp. 1237-1240 (1990).
Keen, M. J., “The culture of rat myeloma and rat hybridoma cells in a protein-free medium”; Cytotechnology 17:193-202 (1995).
Koskimies; “Human Lymphoblastoid Cell Line Producing Specific Antibody against Rh-Antigen D”; Scand. J. Immunol. 11, 73-77, 1980.
Kumpel, B. et al.; “Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity”; Hum. Antibod. Hybridomas, vol. 5, 3 and 4 (1994).
Kumpel, B. et al.; “Human Rh D Monoclonal Antibodies (BRAD-3 and BRAD-5) Cause Accelerated Clearance of RhD+ Red Blood Cells and Suppression of Rh D Immunization in Rh D- Volunteers”; Blood, vol. 86, No. 5, pp. 1701-1709; Sep. 1, 1995.
Kumpel, B. M. et al.; “Human monoclonal anti-D antibodies”; British Journal of Haematology; 1989, 71, 125-129.
Leatherbarrow, R. et al.; “Effector Functions of a Monoclonal Aglycosylated Mouse IgG2a: Binding and Activation of Complement Component C1 and Interaction with Human Monocyte Fc Receptor”; Molecular Immunology, vol. 22, No. 4, pp. 407-415, 1985.
Lifely, M. Robert; et al.; “Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions”
Beliard Roland
Bihoreau Nicolas
Bourel Dominique
De Romeuf Christophe
Glacet Arnaud
Foley & Lardner LLP
Laboratoire Francais du Fractionnement et des Biotechnologies
Ouspenski Ilia
LandOfFree
Method for preparing monoclonal antibodies capable of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preparing monoclonal antibodies capable of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preparing monoclonal antibodies capable of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4096733